Shekar Kumar, MD
Cardiovascular Disease · Greenwood, SCNPI 1811978661
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,768 of the $13,822 with a category attached, or 70.7%. 33 manufacturers reported payments, led by Abbott at 31.6% of the total. Reporting peaked in 2023 at $3,327 and has fallen 56.4% since, to $1,452 in 2025.
Across 517 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Edwards Lifesciences$3K
- Abiomed$1K
- Inari Medical, Inc.$1K
- Boston Scientific$978
- Medtronic$787
- plus $2K from 27 others
What the payments were for
- Grants$550%
- Travel & lodging$4,00029%
- Food & beverage$9,76871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 244 | $4,372 |
| Edwards Lifesciences | 46 | $3,179 |
| Abiomed | 36 | $1,087 |
| Inari Medical, Inc. | 46 | $1,076 |
| Boston Scientific | 13 | $978 |
| Medtronic(2 entities) | 21 | $787 |
| Novartis | 15 | $251 |
| Atricure, Inc. | 6 | $201 |
| Cardiovascular Systems Inc. | 13 | $175 |
| Stryker | 6 | $170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $163 |
| Acist Medical Systems, Inc. | 3 | $162 |
| E.r. Squibb & Sons, L.L.C. | 12 | $160 |
| AstraZeneca | 3 | $151 |
| Amgen | 7 | $133 |
| Shockwave Medical, Inc | 4 | $100 |
| Vital Connect, Inc | 1 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Angiodynamics, Inc. | 2 | $75 |
| Philips North America LLC | 3 | $72 |
| Cvrx, Inc. | 4 | $57 |
| Boehringer Ingelheim | 3 | $52 |
| Penumbra, Inc. | 2 | $40 |
| Biosense Webster, Inc. | 1 | $36 |
| Recor Medical Inc | 1 | $25 |
| Merck | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Pfizer | 1 | $13 |
| Thrombolex, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,627
- ACCULINK$1,452
- FLOWTRIEVER CATHETER, S$451
- Emboshield NAV6 system$256
- CT THROMBECTOMY SYSTEM KIT$246
- CoreValve Evolut$233
- Omnilink Elite vascular stent system$204
- SYMPLICITY G3$164
- SAPIEN 3 Ultra RESILIA$151
- COREVALVE EVOLUT R$149
- CARDIOMEMS$145
- OMNILINK ELITE$132
- NRG RF Transseptal Kit$122
How this compares
$13,822 in reported general payments places this provider in the 85th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $196,562 |
| EntrestoSacubitril/Valsartan | 124 | $140,045 |
| Repatha SureclickEvolocumab | 56 | $50,345 |
| BrilintaTicagrelor | 67 | $35,079 |
| JardianceEmpagliflozin | 13 | $14,498 |
| Praluent PenAlirocumab | 17 | $11,520 |
| Ranolazine ErRanolazine | 93 | $10,585 |
| Metoprolol Succinate | 289 | $4,565 |
| ClopidogrelClopidogrel Bisulfate | 395 | $3,792 |
| Rosuvastatin Calcium | 137 | $2,348 |
| Potassium Chloride | 77 | $2,327 |
| Atorvastatin Calcium | 229 | $2,275 |
| Losartan Potassium | 126 | $1,375 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 127 | $1,286 |
| Carvedilol | 169 | $1,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $196,562193 claims |
| NovartisEntresto | $251 | $140,045124 claims |
| AstraZenecaBrilinta | $151 | $35,07967 claims |
| Boehringer IngelheimJardiance | $52 | $14,49813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Greenwood
- Paul KimGreenwood$11K
- Thomas PritchardGreenwood$11K
- Ned FreemanGreenwood$10K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.